• ARCA EGFP mRNA (5-moUTP): Precision Polyadenylated mRNA for

  2026-06-29

  ARCA EGFP mRNA (5-moUTP) redefines polyadenylated mRNA transfection in mammalian cells by coupling immune-silent, high-stability chemistry with direct fluorescence readout. Its proprietary ARCA cap and 5-methoxyuridine modifications yield unmatched reproducibility and translational efficiency for fluorescence-based assay development and troubleshooting.

• Doxorubicin Hydrochloride: Innovations in Liposomal Delivery

  2026-06-28

  Explore how Doxorubicin hydrochloride (Adriamycin HCl) is revolutionizing cancer chemotherapy research through advances in dual-loaded liposomal delivery and precise assay methods. This deep dive highlights unique technical insights and practical implications for maximizing experimental reproducibility.

• Catalpol’s Multifaceted Anticancer Mechanisms: A Review Anal

  2026-06-27

  This comprehensive review evaluates catalpol, a plant-derived iridoid glycoside, for its diverse anticancer activities across in vitro and animal models. The paper highlights catalpol’s modulation of apoptosis, metastasis, and key signaling pathways, providing a mechanistic basis for its potential as an adjunct in cancer therapy.

• CD44-Driven Metabolic Rewiring in IDH-Mutant AML: A Targetab

  2026-06-26

  This study uncovers how CD44 upregulation in IDH-mutant leukemia orchestrates metabolic rewiring to sustain NADPH production and drive pathological 2-hydroxyglutarate synthesis. The findings highlight a feedforward metabolic pathway and propose that combined targeting of mutant IDH1 and CD44 may overcome resistance in acute myeloid leukemia.

• CD44-Mediated Metabolic Rewiring in IDH-Mutant Leukemia

  2026-06-26

  This study reveals that CD44 upregulation in IDH-mutant leukemia orchestrates metabolic rewiring that sustains NADPH production and oncometabolite 2-hydroxyglutarate synthesis. Targeting the CD44 pathway, especially in combination with mutant IDH1 inhibition, emerges as a promising strategy to overcome resistance and improve outcomes in acute myeloid leukemia research.

• 7-AAD Cell Viability Assay Kit: Precision for Apoptosis Dete

  2026-06-25

  The 7-AAD Cell Viability Assay Kit empowers modern cell biology and immunotherapy workflows with high-fidelity necrosis and apoptosis detection, minimizing spectral overlap in multiplexed assays. Its robust compatibility with flow cytometry and fluorescence microscopy makes it a gold standard for researchers optimizing CAR-T cell development.

• Phalloidin (B7678): Technical Guidance for Actin Filament St

  2026-06-25

  Phalloidin (SKU B7678) addresses the need for robust, high-specificity stabilization and visualization of filamentous actin (F-actin) in fixed or permeabilized samples. It is not intended for live-cell imaging or for studies requiring reversible actin interactions, making it optimal for static cytoskeletal analysis.

• Fatty Acid Signaling Remodels Hepatic Translation in Fasting

  2026-06-24

  Yang et al. (2024) identify a novel mechanism by which fasting-induced long-chain fatty acids, such as linoleic acid (C18:2(9Z,12Z)), selectively remodel hepatic protein translation to support ketogenesis via the AMPK-MNK-eIF4E axis. This work reveals a direct link between dietary lipid signaling, translational control, and cancer vulnerability, offering new mechanistic insight for metabolic and cancer research.

• CmOGD2-Driven Ferroptosis Enhances Citrus Canker Resistance

  2026-06-23

  This study reveals how the 2-oxoglutarate-dependent dioxygenase CmOGD2 in Citron C-05 orchestrates iron uptake and reactive oxygen species (ROS) accumulation, leading to ferroptosis and increased resistance against Xanthomonas-induced citrus canker. The work uncovers a sophisticated regulatory network involving feedback loops and pathogen effectors that shape plant defense, offering new avenues for research on redox regulation and host-pathogen interactions.

• Irinotecan (CPT-11): Advanced Workflows in Colorectal Cancer

  2026-06-23

  Harness Irinotecan's unique topoisomerase I inhibition to model DNA damage and apoptosis in complex tumor systems. Explore robust protocol enhancements, advanced assembloid integration, and troubleshooting insights that set your colorectal cancer research apart.

• Amikacin (BAY416651): Next-Generation Targeted Delivery in A

  2026-06-22

  Explore how Amikacin (BAY416651) enables advanced targeted antibiotic delivery and resistance studies. Discover unique insights on dendritic cell-mediated localization and new research protocols for Klebsiella pneumoniae and beyond.

• SMYD2 Inhibition Mitigates Cisplatin-Induced Renal Fibrosis

  2026-06-22

  Chen et al. provide the first in vivo evidence that pharmacological inhibition of SMYD2, via agents such as AZ505, protects against cisplatin-induced renal fibrosis and inflammation. The study establishes SMYD2 as a mechanistically relevant epigenetic regulator in CKD, opening new avenues for targeted intervention in fibrotic kidney disease.

• AG-221 (Enasidenib): Mechanism, Evidence, and Workflow in AM

  2026-06-21

  AG-221 (Enasidenib) is a selective inhibitor of mutant IDH2, demonstrating >90% reduction of the oncometabolite 2-hydroxyglutarate in acute myeloid leukemia (AML) models. The compound induces differentiation in leukemia cells and provides survival benefits in vivo, positioning it as a benchmark tool for IDH2-mutant AML research.

• UHRF1-Mediated DNA Methylation and Osteogenesis in Senile Os

  2026-06-20

  This study uncovers how UHRF1-driven DNA 5-mC modification redistributes super-enhancers and impairs osteogenesis in senile osteoporosis through TGM2-regulated autophagic flux. The integration of multi-omics profiling provides a mechanistic link between epigenetic regulation, enhancer activity, and MSC function, offering new therapeutic targets for age-related bone loss.

• Ceftolozane Sulfate: Applied Workflows and PK/PD Optimizatio

  2026-06-19

  Ceftolozane sulfate empowers researchers to dissect bacterial resistance with precision, thanks to its potent, time-dependent activity and robust stability against AmpC β-lactamases. Explore advanced in vitro and in vivo workflows, actionable protocol enhancements, and troubleshooting strategies that set new standards for PK/PD modeling in antimicrobial research.

16340 records 1/1090 page Next 12345 下5页 Last page